Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Jun. 30, 2020 | Jul. 31, 2020 | |
Document Information [Line Items] | ||
Entity Registrant Name | CEN BIOTECH INC | |
Entity Central Index Key | 0001653821 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Current Reporting Status | Yes | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
Entity Small Business | true | |
Entity Interactive Data Current | Yes | |
Entity Common Stock, Shares Outstanding (in shares) | 27,283,363 | |
Entity Shell Company | false | |
Document Type | 10-Q | |
Document Period End Date | Jun. 30, 2020 | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q2 | |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Jun. 30, 2020 | Dec. 31, 2019 |
Current assets | ||
Cash and cash equivalents | $ 8,440 | $ 3,757 |
Property, plant and improvements | ||
Property and equipment, net | 138,933 | 148,125 |
Other assets | ||
Operating lease right-of-use assets | 195,703 | 229,284 |
Other receivable | 349,003 | 424,110 |
Note receivable - related party | 44,859 | 44,859 |
Advances to CEN Biotech Ukraine LLC - related party | 1,065,328 | 1,065,328 |
Intangible assets, net | 5,168,553 | 5,380,959 |
Total assets | 6,970,819 | 7,296,422 |
Current liabilities | ||
Accounts payable | 241,936 | 181,266 |
Accounts payable – related parties | 8,347 | |
Loans payable | 10,107,513 | 10,121,411 |
Loans payable – related parties | 1,360,845 | 1,362,600 |
Convertible notes payable | 5,894,565 | 5,185,412 |
Convertible notes payable- related parties | 2,558,681 | 2,538,681 |
Accrued interest | 11,140,476 | 9,585,055 |
Accrued interest – related parties | 1,439,324 | 1,274,899 |
Operating lease liabilities | 44,000 | 44,361 |
Accrued expenses | 578,623 | 574,723 |
Total current liabilities | 33,374,310 | 30,868,408 |
Operating lease liabilities, less current portion | 153,184 | 184,263 |
Patent acquisition liability | 720,000 | 720,000 |
Convertible notes, less current portion | 539,880 | 1,038,913 |
Convertible notes - related parties, less current portion | 20,000 | |
Total liabilities | 34,787,374 | 32,831,584 |
Shareholders' deficit | ||
Common stock; unlimited authorized shares; 27,268,363 issued and outstanding and 26,953,363 issued and outstanding as of June 30, 2020 and December 31, 2019, respectively. No par value. | ||
Additional paid-in capital | 16,453,610 | 15,775,010 |
Accumulated deficit | (44,270,165) | (41,310,172) |
Total shareholders’ deficit | (27,816,555) | (25,535,162) |
Total liabilities and shareholders’ deficit | $ 6,970,819 | $ 7,296,422 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares $ / shares in Thousands | 6 Months Ended | 12 Months Ended |
Jun. 30, 2020 | Dec. 31, 2019 | |
Common stock, par value (in dollars per share) | $ 0 | $ 0 |
Common stock, shares issued (in shares) | 27,268,363 | 26,953,363 |
Common stock, shares outstanding (in shares) | 27,268,363 | 26,953,363 |
Common stock, shares authorized | Unlimited | Unlimited |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Operating expenses | ||||
Consulting fees | $ 162,000 | $ 178 | $ 162,077 | $ 19,120 |
Consulting fees – related parties | 31,200 | 37,759 | 62,400 | 68,959 |
Stock based compensation | 196,650 | 546,150 | 393,300 | 713,550 |
General and administrative | 300,597 | 412,527 | 603,420 | 600,212 |
Total operating expenses | 690,447 | 996,614 | 1,221,197 | 1,401,841 |
Loss from operations | (690,447) | (996,614) | (1,221,197) | (1,401,841) |
Other income (expense) | ||||
Interest expense | (800,465) | (714,791) | (1,595,145) | (1,416,679) |
Interest expense – related parties | (106,059) | (114,226) | (211,510) | (227,439) |
Interest income | 1,853 | 2,052 | 3,912 | 4,097 |
Foreign exchange (loss) gain | (64,763) | (27,046) | 63,947 | (51,540) |
Other expense, net | (969,434) | (854,011) | (1,738,796) | (1,691,561) |
Net loss | $ (1,659,881) | $ (1,850,625) | $ (2,959,993) | $ (3,093,402) |
Net loss per share: | ||||
Basic and diluted (in dollars per share) | $ (0.06) | $ (0.07) | $ (0.11) | $ (0.12) |
Weighted average number of shares outstanding | ||||
Basic and diluted (in shares) | 27,207,044 | 26,173,473 | 27,091,577 | 25,836,540 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balances (in shares) at Dec. 31, 2018 | 25,473,363 | |||
Balances at Dec. 31, 2018 | $ 14,393,660 | $ (35,655,053) | $ (21,261,393) | |
Stock-based compensation (in shares) | 1,250,000 | |||
Stock-based compensation | 713,550 | 713,550 | ||
Issuance of common stock – interest shares (in shares) | 90,000 | |||
Issuance of common stock – interest shares | 90,900 | 90,900 | ||
Net loss | (3,093,402) | (3,093,402) | ||
Balances (in shares) at Jun. 30, 2019 | 26,813,363 | |||
Balances at Jun. 30, 2019 | 15,198,110 | (38,748,455) | (23,550,345) | |
Balances (in shares) at Dec. 31, 2019 | 26,953,363 | |||
Balances at Dec. 31, 2019 | 15,775,010 | (41,310,172) | (25,535,162) | |
Stock-based compensation (in shares) | ||||
Stock-based compensation | 393,300 | 393,300 | ||
Issuance of common stock – interest shares (in shares) | 90,000 | |||
Issuance of common stock – interest shares | 64,800 | 64,800 | ||
Net loss | (2,959,993) | (2,959,993) | ||
Issuance of common stock - consulting (in shares) | 225,000 | |||
Issuance of common stock - consulting | 162,000 | 162,000 | ||
Issuance of common stock - settlement of accrued liability | 58,500 | 58,500 | ||
Balances (in shares) at Jun. 30, 2020 | 27,268,363 | |||
Balances at Jun. 30, 2020 | $ 16,453,610 | $ (44,270,165) | $ (27,816,555) |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 6 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | |
Cash flows from operating activities | ||
Net loss | $ (2,959,993) | $ (3,093,402) |
Adjustments to reconcile net loss to net cash used in operating activities | ||
Depreciation | 9,192 | 9,192 |
Amortization | 212,406 | 212,406 |
Lease expense (benefit) | 2,141 | (2,851) |
Stock-based compensation – employees | 393,300 | 713,550 |
Stock-based compensation – non-employees | 162,000 | |
Non-cash interest expense | 1,595,145 | 1,382,764 |
Non-cash interest expense – related parties | 203,510 | 227,439 |
Foreign exchange (gain) loss | (63,947) | 51,540 |
Changes in operating assets and liabilities which (used) provided cash | ||
Other receivable | 75,107 | (1,053) |
Accounts payable | 55,075 | (3,698) |
Accounts payable – related parties | 8,347 | |
Accrued expenses | 62,400 | 89,858 |
Net cash used in operating activities | (245,317) | (414,255) |
Cash flows used in investing activities | ||
Advances to CEN Biotech Ukraine LLC | (120,000) | |
Cash flows provided by financing activities | ||
Issuance of convertible notes | 250,000 | 533,034 |
Repayment of convertible notes | (6,000) | |
Issuance of convertible notes – related parties | 20,000 | |
Net cash provided by financing activities | 250,000 | 547,034 |
Net increase in cash and cash equivalents | 4,683 | 12,779 |
Cash and cash equivalents, beginning of period | 3,757 | 3,193 |
Cash and cash equivalents, end of period | 8,440 | 15,972 |
Supplemental cash flows disclosures | ||
Cash paid for interest | 8,000 | 33,913 |
Non-cash transactions - investing and financing activities | ||
Issuance of common stock - settlement of accrued liability | $ 58,500 |
Note 1 - Basis of Presentation
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] | NOTE 1 The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) set forth in Article 8 X. not not December 31, 2019 There have been no 10 December 31, 2019. Loss per Share Net loss per common share is computed pursuant to ASC 260 10 45. three June 30, 2020 2019, not FINRA Filing On January 27, 2020, 211 no 211 July 31, 2020, not On June 30, 2020 1 6,851,843 Termination and Release Agreement On May 19, 2020 July 31, 2018. No Recently Adopted Accounting Pronouncements No six June 30, 2020. Recent Accounting Pronouncements Not No |
Note 2 - Going Concern Uncertai
Note 2 - Going Concern Uncertainty / Management Plans | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Substantial Doubt about Going Concern [Text Block] | NOTE 2 The accompanying condensed consolidated financial statements have been prepared in contemplating continuation of the Company as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, a substantial doubt has been raised with regard to the ability of the Company to continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. The Company had an accumulated deficit of $44,270,165 June 30, 2020 no not not 6, 7, 8, 9. 19 no not The Company's cash position may not |
Note 3 - Property, Plant and Im
Note 3 - Property, Plant and Improvements, Net | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | NOTE 3 Property and equipment, net consists of the following as of: June 30, 2020 December 31, 2019 Leasehold improvements $ 166,163 $ 166,163 Furniture and equipment 17,668 17,668 Accumulated depreciation (44,898 ) (35,706 ) Net property, plant and improvements $ 138,933 $ 148,125 Depreciation expense was $4,596 three June 30, 2020 2019, $9,192 six June 30, 2020 2019, |
Note 4 - Advances to CEN Biotec
Note 4 - Advances to CEN Biotech Ukraine | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Advances to Related Party [Text Block] | NOTE 4 At both June 30, 2020 December 31, 2019, $1,065,328 12 Bahige (Bill) Chaaban, our Interim Chief Executive Officer and member of our Board of Directors, and Usamakh Saadikh, a member of our Board of Directors, each directly own 25.5% 49% not not |
Note 5 - Intangible Assets
Note 5 - Intangible Assets | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Intangible Assets Disclosure [Text Block] | NOTE 5 On September 12, 2016, August 31, 2016, Material consideration given by Company was: (a) shares of CEN common stock equal to $5 135 $2,161,467 1517 1525 $202,666. The patent remains in the name of Tesla Digital, Inc. until full settlement of the terms of the agreement. In the interim, pursuant to an updated agreement executed on April 15, 2019 In addition, the Company agreed to employ Stevan Pokrajac, by an LED subsidiary that the Company plans to form, but which has not $200,000 In March 2018, $5 one million September 30, 2018. October 4, 2018, December 15, 2018. April 3, 2019, December 31, 2019. March 16, 2020 December 31, 2021.The March 2018 $4,380,000 June 30, 2020 December 31, 2019, $720,000 The Company intends to explore using the patented LED Lighting Technology across manufacturing operations and licensing opportunities across multiple industries such as horticultural, automotive, industrial and commercial lighting. The assets acquired, other than the patent, included certain machinery and raw materials, which were old and non-functioning and accordingly, had no The intangible asset consists of the following: June 30, 2020 December 31, 2019 Lighting patent $ 6,797,000 $ 6,797,000 Accumulated amortization (1,628,447 ) (1,416,041 ) Net $ 5,168,553 $ 5,380,959 As of June 30, 2020 December 31, 2019, no 16 $424,812 2031, $283,215 2032. |
Note 6 - Loans Payable
Note 6 - Loans Payable | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Short-term Debt [Text Block] | NOTE 6 Loans payable consist of the following: June 30, 2020 December 31, 2019 Loan payable to Global Holdings International, LLC, which bears interest at 15% per annum after defaulting on the maturity date of June 30, 2016. This note is secured by the Company's equipment. $ 9,675,000 $ 9,675,000 Mortgage payable in default to ARG & Pals, Inc., for the original amount of CAD 385,000. The mortgage bears interest at 22% per annum, and matured on November 21, 2018. 282,513 296,411 Loan payable in default to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan which matures on August 16, 2020. 50,000 50,000 Loan payable in default to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan which matures on August 16, 2020. 100,000 100,000 Total loans payable (all current) $ 10,107,513 $ 10,121,411 We are in default of $9,675,000 $9,000. not During each of the three June 30, 2020 2019, 18,000 three June 30, 2020 2019, $12,960 $18,180 During each of the six June 30, 2020 2019, 36,000 six June 30, 2020 2019, $25,920 $36,360 |
Note 7 - Loans Payable-Related
Note 7 - Loans Payable-Related Party | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Loans Payable to Related Party [Text Block] | NOTE 7 – LOANS PAYABLE- RELATED PARTY Loans payable - related party consists of the following: June 30, 2020 December 31, 2019 Loans payable in default to the spouse of Bill Chaaban, President of CEN, for the original amounts of CAD 48,630 and USD $198,660, bear interest at 10% per annum. These are unsecured loans that matured on December 31, 2018. $ 234,345 $ 236,100 Loans payable in default to a former director of Creative, former parent company, bear interest at 10% per annum. This are unsecured loans that matured on December 31, 2018. 601,500 601,500 Loan payable in default to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the President of CEN, bearing interest at 8% per annum. This is an unsecured loan that matured on October 2, 2019. R&D Labs Canada is a company owned by Bill Chaaban's spouse. 300,000 300,000 Loan payable in default to the spouse of Joseph Byrne, a 5% shareholder and former CEO of CEN, issued January 12, 2018 with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan that matures on August 16, 2020. 100,000 100,000 Loan payable in default to Alex Tarrabain, a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 common shares per 30-day period. This is an unsecured loan that matures on August 16, 2020. 75,000 75,000 Loan payable in default to Joseph Byrne, a 5% shareholder and former CEO of CEN, issued January 24, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan that matures on August 16, 2020. 50,000 50,000 Total loans payable - related party 1,360,845 1,362,600 Less: current portion 1,360,845 1,362,600 Long-term portion loans payable - related party $ - $ - Attributable related party accrued interest was $513,469 $460,784 June 30, 2020 December 31, 2019, $46,188 $54,428 three June 30, 2020 2019, $91,771 $108,512 six June 30, 2020 2019, During both three June 30, 2020 2019, 27,000 three June 30, 2020 2019, $19,440 $27,270 During both six June 30, 2020 2019, 54,000 six June 30, 2020 2019, $38,880 $54,540 |
Note 8 - Convertible Notes
Note 8 - Convertible Notes | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Long-term Debt [Text Block] | NOTE 8 Convertible notes payable consists of the following: June 30, 2020 December 31, 2019 Convertible note payable, due on demand, for the original amount of CAD 1,104,713, bearing interest at 7% per annum with conversion rights for 335,833 common shares. $ 810,638 $ 850,519 Convertible notes payable to multiple private investors, including certain notes in default, bearing interest at 5% per annum with conversion rights for 3,489,990 common shares, maturing at various dates between May 2018 and June 2022. 5,623,807 5,373,806 Total convertible notes payable 6,434,445 6,224,325 Less current portion 5,894,565 5,185,412 Convertible notes payable, less current portion $ 539,880 $ 1,038,913 These notes may 3,825,823 As of July 31, 2020, $3,474,805 2,147,088 |
Note 9 - Convertible Notes - Re
Note 9 - Convertible Notes - Related Party | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Long-term Convertible Notes Related Party [Text Block] | NOTE 9 – CONVERTIBLE NOTES - RELATED PARTY Convertible notes - related party consists of the following at: June 30, 2020 December 31, 2019 Convertible note due to the spouse of Bill Chaaban, President of CEN, which bears an interest at 12% per annum. This note is convertible to 867,576 common shares with a maturity date of August 17, 2020. $ 1,388,122 $ 1,388,122 Convertible notes in default due to Harold Aubrey de Lavenu, a Director of CEN, bearing interest at 5% per annum. These notes are convertible to 548,980 common shares and matured on March 31, 2019. 878,368 878,368 Convertible note in default due to Alex Tarrabain, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 30,000 common shares and matured on March 31, 2019. 48,000 48,000 Convertible notes due to Joseph Byrne, CEO of CEN, bearing interest at 12% per annum. This note is convertible to 140,120 common shares with a maturity date of August 17, 2020. 224,191 224,191 Convertible note due to Darren Ferris, brother of Ameen Ferris, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 12,500 common shares with a maturity date of June 19, 2021. 20,000 20,000 Total convertible notes payable - related party 2,558,681 2,558,681 Less current portion 2,558,681 2,538,681 Convertible notes payable - related party, less current portion $ - $ 20,000 Attributable related party accrued interest was $925,855 $814,115 June 30, 2020 December 31, 2019, $59,871, $59,798 three June 30, 2020 2019, $119,739 $118,927 six June 30, 2020 2019, These notes may 1,599,176 As of July 31, 2020, $926,368 578,980 |
Note 10 - Income Taxes
Note 10 - Income Taxes | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | NOTE 10 A reconciliation of the effective tax rate of the income tax benefit and the statutory income tax rates applied to the loss before income taxes is as follows for the three six June 30: 2020 2019 Income tax benefit at Canadian statutory rate 26.5 % 26.5 % Valuation allowance (26.5 )% (26.5 )% Effective income tax rate 0 % 0 % As of June 30, 2020, $28,400,000 may 20 2034. may not not June 30, 2020 December 31, 2019: June 30, 2020 December 31, 2019 Deferred tax asset - net operating losses $ 7,500,000 $ 6,800,000 Deferred tax asset valuation allowance (7,500,000 ) (6,800,000 ) Net deferred tax asset $ - $ - The valuation allowance increased (decreased) $600,000 $3,900,000 three June 30, 2020 2019, $700,000 $3,600,000 six June 30, 2020 2019, Company management analyzes its income tax filing positions in Canadian federal and provincial jurisdictions where it is required to file income tax returns, for all open tax years in these jurisdictions, to identify potential uncertain tax positions. As of June 30, 2020, no no no 2016. |
Note 11 - Shareholders' Deficit
Note 11 - Shareholders' Deficit / Stock Activity | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | NOTE 11 The Company is authorized to issue an unlimited number of common shares and an unlimited number of special voting shares. Common shares have no As of June 30, 2020, 5,424,999 |
Note 12 - Related Party Transac
Note 12 - Related Party Transactions | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | NOTE 12 The Company has received loans from several related parties, as described above in Notes 7 9. There are advances of $1,065,328 June 30, 2020 December 31, 2019, 4. December 3, 2017, 51% December 14, 2017, 51% not July 31, 2020, 25.5% 49% not not On July 12, 2017, 5% As of June 30, 2020, 5% $8,347 During the three June 30, 2020 2019, $31,200 $33,800, $62,400 $65,000 six June 30, 2020 2019, June 30, 2020 December 31, 2019, $267,800 $263,900, During 2017, $300,000 $255,141 $44,859 10 2017 2026. No June 30, 2020, The Company leases 20 10.4 two one 27,000 one 53,000 4,000 4 th 2018. Jamaal Shaban (“Lessor”), cousin of Bill Chaaban, leased the 20 January 2017 4,000 five June 30, 2020 December 31, 2019, $49,963 $68,547, $47,028 $65,467, 8% three June 30, 2020 2019, $8,690 $9,106, six June 30, 2020 2019, $17,409 $15,092, third October 2019. The Company also leases office space in Windsor, Ontario from R&D Labs Canada, Inc., whose president is Bill Chaaban. This lease was subsequently assigned to RN Holdings Ltd, a third May 8, 2019 October 1, 2017, 2,608 September 2022, 3,390 June 30, 2020 December 31, 2019, $145,740 $160,737, $150,156 $163,157, 8% three June 30, 2020 2019, $6,928 $7,060, three June 30, 2020 2019, $13,253 $12,039, Maturities of operating lease liabilities were as follows at June 30, 2020: Amount 2020 $ 58,188 2021 49,382 2022 28,130 2023 29,852 2024 29,852 Thereafter 67,167 Total lease payments $ 262,571 Less imputed interest 65,387 Present value of lease liabilities $ 197,184 |
Note 13 - Stock Based Compensat
Note 13 - Stock Based Compensation | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | NOTE 13 Adoption of Equity Compensation Plan On November 29, 2017, 2017 20,000,000 Equity Compensation Grants On November 30, 2017, one 20,000 November 13, 2019); May 20, 2019) May 21, 2019) In addition, as part of this one 1,000,000 550,000 36 1,870,000 1,330,000 36 On June 7, 2018, one 20,000 On June 19, 2018, 125,000 On December 31, 2018, 12,120 On October 1, 2019, 50,000 $36,000 On April 17, 2020, three 225,000 $162,000 Employment Agreements On November 30, 2017, four ● Under the Employment Agreement with Bahige (Bill) Chaaban, President of the Company, Mr. Chaaban will receive compensation in the form of a base annual salary of $31,200 8,750,000 7,400,000 36 November 2020. ● Under the Employment Agreement with Joseph Byrne, Chief Executive Officer of the Company, Mr. Byrne will receive compensation in the form of a base annual salary of $31,200 1,250,000 325,000 36 November 2020. November 13, 2019, April 2, 2020, $58,500, 337,500 not ● Under the Employment Agreement with Richard Boswell, Senior Executive Vice President and Chief Financial Officer of the Company, Mr. Boswell will receive compensation in the form of a base annual salary of $31,200 4,500,000 4,140,000 36 November 2020. ● Under the Employment Agreement with Brian Payne, Vice President of the Company, Mr. Payne will receive compensation in the form of a base annual salary of $31,200 750,000 300,000 36 November 2020. On May 16, 2019, one one May 21, 2019 ( July 2017, In conjunction with the above, on May 16, 2019, ● Under the Employment Agreement with Alex Tarrabain, Chief Financial Officer and as one $31,200 1,250,000 350,000 36 May 2022. Restricted Stock Awards The total grant-date fair value of the restricted shares noted in the employment agreements and equity compensation grants sections above was $12,896,241 $12,734,241 June 30, 2020 December 31, 2019, three six June 30, 2020, 225,000 $162,000 three six June 30, 2019, 1,250,000 $ 1,262,500 three During the three June 30, 2020 2019, 900,000 712,500, six June 30, 2020 2019, 1,237,500 1,050,000, $459,000 $588,000 three June 30, 2020 2019, $697,500 $797,250 six June 30, 2020 2019, Compensation expense recognized in connection with the restricted stock awards was $196,650 $546,150 three June 30, 2020 2019, $393,300 $713,550 six June 30, 2020 2019, $162,000 three six June 30, 2020. Non-vested restricted stock award activity for the six June 30, 2020 2019 Number of Shares Weighted- Average Grant Date Fair Value per Share Weighted- Average Remaining Contractual Term (Years) Non-vested at January 1, 2019 2,612,500 $ 0.62 2.00 Granted 1,250,000 1.01 - Vested (1,050,000 ) 0.83 - Forfeited - - - Non-vested at June 30, 2019 2,812,500 $ 0.74 1.97 Non-vested at January 1, 2020 2,025,000 $ 0.76 1.54 Granted 225,000 0.72 - Vested (1,237,500 ) 0.68 - Forfeited - - - Non-vested at June 30, 2020 1,012,500 $ 0.84 1.35 The fair value of the restricted stock grants was based on the valuation of a third $782,250 June 30, 2020. As of June 30, 2020, $782,250, May 2022. |
Note 14 - Net Loss Per Share
Note 14 - Net Loss Per Share | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | NOTE 1 4 – NET LOSS PER SHARE During periods when there is a net loss, all potentially dilutive shares are anti-dilutive and are excluded from the calculation of diluted net loss per share. Based on the Company's application of the as-converted and treasury stock methods, all common stock equivalents were excluded from the computation of diluted earnings per share due to net losses as of June 30, 2020 2019. three six June 30, 2020 2019 Three-months Ended June 30, Six-months Ended June 30, 2020 2019 2020 2019 Convertible debt 5,482,166 4,882,922 5,376,040 4,746,243 |
Note 15 - Contingency
Note 15 - Contingency | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | NOTE 1 5 – CONTINGENCY In connection with the distribution by Creative of CEN's common stock on February 29, 2016 10 May 4, 2016 5 not |
Note 16 - Fair Value Disclosure
Note 16 - Fair Value Disclosures | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | NOTE 1 6 – FAIR VALUE DISCLOSURES Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value. The fair value of the Company's financial instruments are as follows: Fair Value Measured at Reporting Date Using Carrying Amount Level 1 Level 2 Level 3 Fair Value At June 30, 2020: Cash and cash equivalents $ 8,440 $ - $ 8,440 $ - $ 8,440 Other receivables $ 349,003 $ - $ - $ 349,003 $ 349,003 Note receivable - related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to CEN Biotech Ukraine, LLC - related party $ 1,065,328 $ - $ - $ 1,065,328 $ 1,065,328 Loans payable $ 10,107,513 $ - $ - $ 10,107,513 $ 10,107,513 Loans payable – related parties $ 1,360,845 $ - $ - $ - $ - Patent acquisition liability $ 720,000 $ - $ - $ 720,000 $ 720,000 Convertible notes payable $ 6,434,445 $ - $ - $ 7,283,393 $ 7,283,393 Convertible notes payable – related parties $ 2,558,681 $ - $ - $ - $ - Carrying Amount Level 1 Level 2 Level 3 Fair Value At December 31, 2019: Cash and cash equivalents $ 3,757 $ - $ 3,757 $ - $ 3,757 Other receivables $ 424,110 $ - $ - $ 424,110 $ 424,110 Note receivable - related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to CEN Biotech Ukraine, LLC - related party $ 1,065,328 $ - $ - $ 1,065,328 $ 1,065,328 Loans payable $ 10,121,411 $ - $ - $ 10,121,411 $ 10,121,411 Loans payable – related parties $ 1,362,600 $ - $ - $ - $ - Patent acquisition liability $ 720,000 $ - $ - $ 720,000 $ 720,000 Convertible notes payable $ 6,224,325 $ - $ - $ 6,918,486 $ 6,918,486 Convertible notes payable – related parties $ 2,558,681 $ - $ - $ - $ - The fair values of other receivables (including related accrued interest), note receivable - related party, and advances to CEN Biotech Ukraine, LLC approximate carrying value due to the terms of the instruments. The fair value of the loans payable approximates carrying value due to the terms of such instruments and applicable interest rates. The fair value of convertible notes payable is based on the par value plus accrued interest through the date of reporting due to the terms of such instruments and interest rates. It is not The fair value of the patent acquisition liability is based upon a valuation report obtained from a 3 rd |
Note 17 - Subsequent Events
Note 17 - Subsequent Events | 6 Months Ended |
Jun. 30, 2020 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | NOTE 17 Since the period ending June 30, 2020 $24,000 15,000 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2020 | |
Accounting Policies [Abstract] | |
Earnings Per Share, Policy [Policy Text Block] | Loss per Share Net loss per common share is computed pursuant to ASC 260 10 45. three June 30, 2020 2019, not |
FINRA Filing Policy [Policy Text Block] | FINRA Filing On January 27, 2020, 211 no 211 July 31, 2020, not On June 30, 2020 1 6,851,843 |
Termination and Release Agreement Policy [Policy Text Block] | Termination and Release Agreement On May 19, 2020 July 31, 2018. No |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Adopted Accounting Pronouncements No six June 30, 2020. Recent Accounting Pronouncements Not No |
Note 3 - Property, Plant and _2
Note 3 - Property, Plant and Improvements, Net (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | June 30, 2020 December 31, 2019 Leasehold improvements $ 166,163 $ 166,163 Furniture and equipment 17,668 17,668 Accumulated depreciation (44,898 ) (35,706 ) Net property, plant and improvements $ 138,933 $ 148,125 |
Note 5 - Intangible Assets (Tab
Note 5 - Intangible Assets (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Notes Tables | |
Schedule of Finite-Lived Intangible Assets [Table Text Block] | June 30, 2020 December 31, 2019 Lighting patent $ 6,797,000 $ 6,797,000 Accumulated amortization (1,628,447 ) (1,416,041 ) Net $ 5,168,553 $ 5,380,959 |
Note 6 - Loans Payable (Tables)
Note 6 - Loans Payable (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Notes Tables | |
Schedule of Short-term Debt [Table Text Block] | June 30, 2020 December 31, 2019 Loan payable to Global Holdings International, LLC, which bears interest at 15% per annum after defaulting on the maturity date of June 30, 2016. This note is secured by the Company's equipment. $ 9,675,000 $ 9,675,000 Mortgage payable in default to ARG & Pals, Inc., for the original amount of CAD 385,000. The mortgage bears interest at 22% per annum, and matured on November 21, 2018. 282,513 296,411 Loan payable in default to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan which matures on August 16, 2020. 50,000 50,000 Loan payable in default to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan which matures on August 16, 2020. 100,000 100,000 Total loans payable (all current) $ 10,107,513 $ 10,121,411 |
Note 7 - Loans Payable-Relate_2
Note 7 - Loans Payable-Related Party (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Notes Tables | |
Schedule of Loans Payable to Related Party [Table Text Block] | June 30, 2020 December 31, 2019 Loans payable in default to the spouse of Bill Chaaban, President of CEN, for the original amounts of CAD 48,630 and USD $198,660, bear interest at 10% per annum. These are unsecured loans that matured on December 31, 2018. $ 234,345 $ 236,100 Loans payable in default to a former director of Creative, former parent company, bear interest at 10% per annum. This are unsecured loans that matured on December 31, 2018. 601,500 601,500 Loan payable in default to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the President of CEN, bearing interest at 8% per annum. This is an unsecured loan that matured on October 2, 2019. R&D Labs Canada is a company owned by Bill Chaaban's spouse. 300,000 300,000 Loan payable in default to the spouse of Joseph Byrne, a 5% shareholder and former CEO of CEN, issued January 12, 2018 with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan that matures on August 16, 2020. 100,000 100,000 Loan payable in default to Alex Tarrabain, a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 common shares per 30-day period. This is an unsecured loan that matures on August 16, 2020. 75,000 75,000 Loan payable in default to Joseph Byrne, a 5% shareholder and former CEO of CEN, issued January 24, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan that matures on August 16, 2020. 50,000 50,000 Total loans payable - related party 1,360,845 1,362,600 Less: current portion 1,360,845 1,362,600 Long-term portion loans payable - related party $ - $ - |
Note 8 - Convertible Notes (Tab
Note 8 - Convertible Notes (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Notes Tables | |
Schedule of Long-term Debt Instruments [Table Text Block] | June 30, 2020 December 31, 2019 Convertible note payable, due on demand, for the original amount of CAD 1,104,713, bearing interest at 7% per annum with conversion rights for 335,833 common shares. $ 810,638 $ 850,519 Convertible notes payable to multiple private investors, including certain notes in default, bearing interest at 5% per annum with conversion rights for 3,489,990 common shares, maturing at various dates between May 2018 and June 2022. 5,623,807 5,373,806 Total convertible notes payable 6,434,445 6,224,325 Less current portion 5,894,565 5,185,412 Convertible notes payable, less current portion $ 539,880 $ 1,038,913 |
Note 9 - Convertible Notes - _2
Note 9 - Convertible Notes - Related Party (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Notes Tables | |
Schedule of Convertible Notes Payable to Related Party [Table Text Block] | June 30, 2020 December 31, 2019 Convertible note due to the spouse of Bill Chaaban, President of CEN, which bears an interest at 12% per annum. This note is convertible to 867,576 common shares with a maturity date of August 17, 2020. $ 1,388,122 $ 1,388,122 Convertible notes in default due to Harold Aubrey de Lavenu, a Director of CEN, bearing interest at 5% per annum. These notes are convertible to 548,980 common shares and matured on March 31, 2019. 878,368 878,368 Convertible note in default due to Alex Tarrabain, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 30,000 common shares and matured on March 31, 2019. 48,000 48,000 Convertible notes due to Joseph Byrne, CEO of CEN, bearing interest at 12% per annum. This note is convertible to 140,120 common shares with a maturity date of August 17, 2020. 224,191 224,191 Convertible note due to Darren Ferris, brother of Ameen Ferris, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 12,500 common shares with a maturity date of June 19, 2021. 20,000 20,000 Total convertible notes payable - related party 2,558,681 2,558,681 Less current portion 2,558,681 2,538,681 Convertible notes payable - related party, less current portion $ - $ 20,000 |
Note 10 - Income Taxes (Tables)
Note 10 - Income Taxes (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Notes Tables | |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | 2020 2019 Income tax benefit at Canadian statutory rate 26.5 % 26.5 % Valuation allowance (26.5 )% (26.5 )% Effective income tax rate 0 % 0 % |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | June 30, 2020 December 31, 2019 Deferred tax asset - net operating losses $ 7,500,000 $ 6,800,000 Deferred tax asset valuation allowance (7,500,000 ) (6,800,000 ) Net deferred tax asset $ - $ - |
Note 12 - Related Party Trans_2
Note 12 - Related Party Transactions (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Notes Tables | |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | Amount 2020 $ 58,188 2021 49,382 2022 28,130 2023 29,852 2024 29,852 Thereafter 67,167 Total lease payments $ 262,571 Less imputed interest 65,387 Present value of lease liabilities $ 197,184 |
Note 13 - Stock Based Compens_2
Note 13 - Stock Based Compensation (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Notes Tables | |
Nonvested Restricted Stock Shares Activity [Table Text Block] | Number of Shares Weighted- Average Grant Date Fair Value per Share Weighted- Average Remaining Contractual Term (Years) Non-vested at January 1, 2019 2,612,500 $ 0.62 2.00 Granted 1,250,000 1.01 - Vested (1,050,000 ) 0.83 - Forfeited - - - Non-vested at June 30, 2019 2,812,500 $ 0.74 1.97 Non-vested at January 1, 2020 2,025,000 $ 0.76 1.54 Granted 225,000 0.72 - Vested (1,237,500 ) 0.68 - Forfeited - - - Non-vested at June 30, 2020 1,012,500 $ 0.84 1.35 |
Note 14 - Net Loss Per Share (T
Note 14 - Net Loss Per Share (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Notes Tables | |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Three-months Ended June 30, Six-months Ended June 30, 2020 2019 2020 2019 Convertible debt 5,482,166 4,882,922 5,376,040 4,746,243 |
Note 16 - Fair Value Disclosu_2
Note 16 - Fair Value Disclosures (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Notes Tables | |
Fair Value, by Balance Sheet Grouping [Table Text Block] | Fair Value Measured at Reporting Date Using Carrying Amount Level 1 Level 2 Level 3 Fair Value At June 30, 2020: Cash and cash equivalents $ 8,440 $ - $ 8,440 $ - $ 8,440 Other receivables $ 349,003 $ - $ - $ 349,003 $ 349,003 Note receivable - related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to CEN Biotech Ukraine, LLC - related party $ 1,065,328 $ - $ - $ 1,065,328 $ 1,065,328 Loans payable $ 10,107,513 $ - $ - $ 10,107,513 $ 10,107,513 Loans payable – related parties $ 1,360,845 $ - $ - $ - $ - Patent acquisition liability $ 720,000 $ - $ - $ 720,000 $ 720,000 Convertible notes payable $ 6,434,445 $ - $ - $ 7,283,393 $ 7,283,393 Convertible notes payable – related parties $ 2,558,681 $ - $ - $ - $ - Carrying Amount Level 1 Level 2 Level 3 Fair Value At December 31, 2019: Cash and cash equivalents $ 3,757 $ - $ 3,757 $ - $ 3,757 Other receivables $ 424,110 $ - $ - $ 424,110 $ 424,110 Note receivable - related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to CEN Biotech Ukraine, LLC - related party $ 1,065,328 $ - $ - $ 1,065,328 $ 1,065,328 Loans payable $ 10,121,411 $ - $ - $ 10,121,411 $ 10,121,411 Loans payable – related parties $ 1,362,600 $ - $ - $ - $ - Patent acquisition liability $ 720,000 $ - $ - $ 720,000 $ 720,000 Convertible notes payable $ 6,224,325 $ - $ - $ 6,918,486 $ 6,918,486 Convertible notes payable – related parties $ 2,558,681 $ - $ - $ - $ - |
Note 1 - Basis of Presentatio_2
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) | 6 Months Ended |
Jun. 30, 2020shares | |
Common Stock, Shares Authorized for Resale, Shares (in shares) | 6,851,843 |
Note 2 - Going Concern Uncert_2
Note 2 - Going Concern Uncertainty / Management Plans (Details Textual) - USD ($) | Jun. 30, 2020 | Dec. 31, 2019 |
Retained Earnings (Accumulated Deficit), Ending Balance | $ (44,270,165) | $ (41,310,172) |
Note 3 - Property, Plant and _3
Note 3 - Property, Plant and Improvements, Net (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Depreciation, Total | $ 4,596 | $ 4,596 | $ 9,192 | $ 9,192 |
Note 3 - Property, Plant and _4
Note 3 - Property, Plant and Improvements, Net - Property, Plant and Improvement Placed in Service (Details) - USD ($) | Jun. 30, 2020 | Dec. 31, 2019 |
Accumulated depreciation | $ (44,898) | $ (35,706) |
Net property, plant and improvements | 138,933 | 148,125 |
Leasehold Improvements [Member] | ||
Property, plant and equipment, gross | 166,163 | 166,163 |
Furniture and Equipment [Member] | ||
Property, plant and equipment, gross | $ 17,668 | $ 17,668 |
Note 4 - Advances to CEN Biot_2
Note 4 - Advances to CEN Biotech Ukraine (Details Textual) - USD ($) | Jun. 30, 2020 | Dec. 31, 2019 | Dec. 14, 2017 | Dec. 02, 2017 |
XN Pharma [Member] | CEN Biotech Ukraine [Member] | ||||
Ownership Percentage | 49.00% | 49.00% | ||
CEN Biotech Ukraine [Member] | ||||
Due from Related Parties, Total | $ 1,065,328 | $ 1,065,328 | ||
Percentage of Related Party's Equity Interest Owned by Director | 51.00% | |||
CEN Biotech Ukraine [Member] | Bahige (Bill) Chaaban [Member] | ||||
Percentage of Related Party's Equity Interest Owned by Director | 25.50% | |||
CEN Biotech Ukraine [Member] | Usamakh Saadikh [Member] | ||||
Percentage of Related Party's Equity Interest Owned by Director | 25.50% |
Note 5 - Intangible Assets (Det
Note 5 - Intangible Assets (Details Textual) - USD ($) | Apr. 03, 2019 | Sep. 12, 2016 | Mar. 31, 2018 | Jun. 30, 2020 | Sep. 30, 2018 | Dec. 31, 2019 |
Stock Issued During Period, Value, Purchase of Assets | $ 5,000,000 | |||||
Development of Acquired Technology, Annual Compensation for Specialist | $ 200,000 | |||||
Noncash or Part Noncash Acquisition, Noncash Consideration, Liability Incurred | $ 4,380,000 | |||||
Contingent Consideration Classified as Equity, Fair Value Disclosure | $ 720,000 | $ 720,000 | ||||
Impairment of Real Estate | $ 0 | $ 0 | ||||
Finite-Lived Intangible Asset, Useful Life (Year) | 16 years | |||||
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months | $ 424,812 | |||||
Finite-Lived Intangible Asset, Expected Amortization, Year Twelve | 283,215 | |||||
Finite-Lived Intangible Asset, Expected Amortization, Year Two | 424,812 | |||||
Finite-Lived Intangible Asset, Expected Amortization, Year Three | 424,812 | |||||
Finite-Lived Intangible Asset, Expected Amortization, Year Four | 424,812 | |||||
Finite-Lived Intangible Asset, Expected Amortization, Year Five | 424,812 | |||||
Finite-Lived Intangible Asset, Expected Amortization, Year Six | 424,812 | |||||
Finite-Lived Intangible Asset, Expected Amortization, Year Seven | 424,812 | |||||
Finite-Lived Intangible Asset, Expected Amortization, Year Eight | 424,812 | |||||
Finite-Lived Intangible Asset, Expected Amortization, Year Nine | 424,812 | |||||
Finite-Lived Intangible Asset, Expected Amortization, Year Ten | 424,812 | |||||
Finite-Lived Intangible Asset, Expected Amortization, Year Eleven | $ 424,812 | |||||
Tesla Digital [Member] | ||||||
Stock Issued During Period, Shares, Purchase of Assets (in shares) | 1,000,000 | |||||
Patented Technology [Member] | ||||||
Stock Issued During Period, Value, Purchase of Assets | 5,000,000 | |||||
Noncash or Part Noncash Acquisition, Noncash Consideration, Carrying Value of Properties to be Transferred | 2,161,467 | |||||
Noncash or Part Noncash Acquisition, Noncash Consideration, Original Cost of Property Transferred | $ 202,666 |
Note 5 - Intangible Assets - In
Note 5 - Intangible Assets - Intangible Assets (Details) - USD ($) | Jun. 30, 2020 | Dec. 31, 2019 |
Lighting patent | $ 6,797,000 | $ 6,797,000 |
Accumulated amortization | (1,628,447) | (1,416,041) |
Net | $ 5,168,553 | $ 5,380,959 |
Note 6 - Loans Payable (Details
Note 6 - Loans Payable (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Debt Instrument, Debt Default, Amount | $ 9,675,000 | $ 9,675,000 | ||
Equipment Pledged as Collateral | $ 9,000 | 9,000 | ||
Stock Issued During Period, Value, New Issues | $ 64,800 | $ 90,900 | ||
Individual Lenders [Member] | ||||
Stock Issued During Period, Shares, New Issues (in shares) | 18,000 | 18,000 | 36,000 | 36,000 |
Stock Issued During Period, Value, New Issues | $ 12,960 | $ 18,180 | $ 25,920 | $ 36,360 |
Note 6 - Loans Payable - Loans
Note 6 - Loans Payable - Loans Payable (Details) - USD ($) | Jun. 30, 2020 | Dec. 31, 2019 |
Loans payable | $ 10,107,513 | $ 10,121,411 |
Short-term Loan Payable to Global Holdings International, LLC [Member] | ||
Loans payable | 9,675,000 | 9,675,000 |
Short-term Mortgage Payable to ARG & Pals, Inc. [Member] | ||
Loans payable | 282,513 | 296,411 |
Short-term Loan Payable to an Individual [Member] | ||
Loans payable | 50,000 | 50,000 |
Second Short-term Loan Payable to an Individual [Member] | ||
Loans payable | $ 100,000 | $ 100,000 |
Note 6 - Loans Payable - Loan_2
Note 6 - Loans Payable - Loans Payable (Details) (Parentheticals) - CAD ($) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2020 | Dec. 31, 2019 | |
Short-term Loan Payable to Global Holdings International, LLC [Member] | ||
Interest Rate | 15.00% | 15.00% |
Maturity Date | Jun. 30, 2016 | Jun. 30, 2016 |
Short-term Mortgage Payable to ARG & Pals, Inc. [Member] | ||
Interest Rate | 22.00% | 22.00% |
Maturity Date | Nov. 21, 2018 | Nov. 21, 2018 |
Original Amount | $ 385,000 | $ 385,000 |
Short-term Loan Payable to an Individual [Member] | ||
Maturity Date | Aug. 16, 2020 | Aug. 16, 2020 |
Share Interest (in shares) | 2,000 | 2,000 |
Second Short-term Loan Payable to an Individual [Member] | ||
Maturity Date | Aug. 16, 2020 | Aug. 16, 2020 |
Share Interest (in shares) | 4,000 | 4,000 |
Note 7 - Loans Payable-Relate_3
Note 7 - Loans Payable-Related Party (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | Dec. 31, 2019 | |
Interest Expense, Related Party | $ 106,059 | $ 114,226 | $ 211,510 | $ 227,439 | |
Stock Issued During Period, Value, New Issues | $ 64,800 | $ 90,900 | |||
Related Parties Lenders [Member] | |||||
Stock Issued During Period, Shares, New Issues (in shares) | 27,000 | 27,000 | 54,000 | 54,000 | |
Stock Issued During Period, Value, New Issues | $ 19,440 | $ 27,270 | $ 38,880 | $ 54,540 | |
Loans Payable to Related Party [Member] | |||||
Interest Payable, Related Party | 513,469 | 513,469 | $ 460,784 | ||
Interest Expense, Related Party | $ 46,188 | $ 54,428 | $ 91,771 | $ 108,512 |
Note 7 - Loans Payable-Relate_4
Note 7 - Loans Payable-Related Party - Loans Payable to Related Parties (Details) - Loans Payable to Related Party [Member] - USD ($) | Jun. 30, 2020 | Dec. 31, 2019 |
Long-term Debt | $ 1,360,845 | $ 1,362,600 |
Less: current portion | 1,360,845 | 1,362,600 |
Long-term portion loans payable - related party | ||
Bill Chaaban, President of Cen Biotech [Member] | ||
Long-term Debt | 234,345 | 236,100 |
Creative Edge [Member] | ||
Long-term Debt | 601,500 | 601,500 |
R&D Labs Canada, Inc [Member] | ||
Long-term Debt | 300,000 | 300,000 |
Spouse of Joseph Byrne, CEO of CEN Biotech [Member] | ||
Long-term Debt | 100,000 | 100,000 |
Director, Alex Tarrabain [Member] | ||
Long-term Debt | 75,000 | 75,000 |
Joseph Byrne [Member] | ||
Long-term Debt | $ 50,000 | $ 50,000 |
Note 7 - Loans Payable-Relate_5
Note 7 - Loans Payable-Related Party - Loans Payable to Related Parties (Details) (Parentheticals) | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2020USD ($)shares | Dec. 31, 2019USD ($)shares | Jun. 30, 2020CAD ($)shares | Dec. 31, 2019CAD ($)shares | |
Director, Alex Tarrabain [Member] | ||||
Interest Rate | 5.00% | 5.00% | 5.00% | 5.00% |
Maturity Date | Mar. 31, 2019 | Mar. 31, 2019 | ||
Loans Payable to Related Party [Member] | Bill Chaaban, President of Cen Biotech [Member] | ||||
Interest Rate | 10.00% | 10.00% | 10.00% | 10.00% |
Maturity Date | Dec. 31, 2018 | Dec. 31, 2018 | ||
Loans Payable to Related Party [Member] | Bill Chaaban, President of Cen Biotech [Member] | Loans Payable in Default, One [Member] | ||||
Original Amount | $ | $ 48,630 | $ 48,630 | ||
Loans Payable to Related Party [Member] | Bill Chaaban, President of Cen Biotech [Member] | Loans Payable in Default, Two [Member] | ||||
Original Amount | $ | $ 198,660 | $ 198,660 | ||
Loans Payable to Related Party [Member] | Creative Edge [Member] | ||||
Interest Rate | 10.00% | 10.00% | 10.00% | 10.00% |
Maturity Date | Dec. 31, 2018 | Dec. 31, 2018 | ||
Loans Payable to Related Party [Member] | R&D Labs Canada, Inc [Member] | ||||
Interest Rate | 8.00% | 8.00% | 8.00% | 8.00% |
Maturity Date | Oct. 2, 2019 | Oct. 2, 2019 | ||
Loans Payable to Related Party [Member] | Spouse of Joseph Byrne, CEO of CEN Biotech [Member] | ||||
Interest Rate | 5.00% | 5.00% | 5.00% | 5.00% |
Maturity Date | Jun. 16, 2020 | Jun. 16, 2020 | ||
Share Interest (in shares) | 4,000 | 4,000 | 4,000 | 4,000 |
Loans Payable to Related Party [Member] | Director, Alex Tarrabain [Member] | ||||
Maturity Date | Jun. 16, 2020 | Jun. 16, 2020 | ||
Share Interest (in shares) | 3,000 | 3,000 | 3,000 | 3,000 |
Loans Payable to Related Party [Member] | Joseph Byrne [Member] | ||||
Interest Rate | 5.00% | 5.00% | 5.00% | 5.00% |
Maturity Date | Aug. 16, 2020 | Aug. 16, 2020 | ||
Share Interest (in shares) | 2,000 | 2,000 | 2,000 | 2,000 |
Note 8 - Convertible Notes (Det
Note 8 - Convertible Notes (Details Textual) | Jul. 14, 2020USD ($) | Jul. 30, 2020 | Jun. 30, 2020USD ($) |
Debt Instrument, Debt Default, Amount | $ 9,675,000 | ||
Subsequent Event [Member] | |||
Debt Instrument, Convertible, Number of Equity Instruments | 15,000 | ||
Convertible Debt [Member] | |||
Debt Instrument, Convertible, Number of Equity Instruments | 3,825,823 | ||
Convertible Debt [Member] | Subsequent Event [Member] | |||
Debt Instrument, Convertible, Number of Equity Instruments | 2,147,088 | ||
Debt Instrument, Debt Default, Amount | $ 3,474,805 |
Note 8 - Convertible Notes - Co
Note 8 - Convertible Notes - Convertible Notes (Details) - Convertible Debt [Member] - USD ($) | Jun. 30, 2020 | Dec. 31, 2019 |
Long-term Debt | $ 6,434,445 | $ 6,224,325 |
Less: current portion | 5,894,565 | 5,185,412 |
Long-term portion loans payable - related party | 539,880 | 1,038,913 |
Convertible Notes 1[Member] | ||
Long-term Debt | 810,638 | 850,519 |
Convertible Notes 2 [Member] | ||
Long-term Debt | $ 5,623,807 | $ 5,373,806 |
Note 8 - Convertible Notes - _2
Note 8 - Convertible Notes - Convertible Notes (Details) (Parentheticals) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2020CAD ($) | Dec. 31, 2019CAD ($) | |
Convertible Notes 2 [Member] | ||
Interest Rate | 5.00% | 5.00% |
Conversion Rights | 3,489,990 | 3,489,990 |
Maturing Dates Range Start | May 1, 2018 | May 1, 2018 |
Maturing Dates Range End | Jun. 30, 2022 | Jun. 30, 2022 |
Convertible Debt [Member] | ||
Conversion Rights | 3,825,823 | |
Convertible Debt [Member] | Convertible Notes 1[Member] | ||
Interest Rate | 7.00% | 7.00% |
Conversion Rights | 335,833 | 335,833 |
Original Amount | $ 1,104,713 | $ 1,104,713 |
Note 9 - Convertible Notes - _3
Note 9 - Convertible Notes - Related Party (Details Textual) | Jul. 12, 2020USD ($) | Jul. 30, 2020 | Jun. 30, 2020USD ($) | Jun. 30, 2019USD ($) | Jun. 30, 2020USD ($) | Jun. 30, 2019USD ($) | Dec. 31, 2019USD ($) |
Interest Expense, Related Party | $ 106,059 | $ 114,226 | $ 211,510 | $ 227,439 | |||
Debt Instrument, Debt Default, Amount | 9,675,000 | 9,675,000 | |||||
Subsequent Event [Member] | |||||||
Debt Instrument, Convertible, Number of Equity Instruments | 15,000 | ||||||
Convertible Debt Payable to Related Party [Member] | |||||||
Interest Payable, Related Party | 925,855 | 925,855 | $ 814,115 | ||||
Interest Expense, Related Party | $ 59,871 | $ 59,798 | $ 119,739 | $ 118,927 | |||
Debt Instrument, Convertible, Number of Equity Instruments | 1,599,176 | ||||||
Convertible Debt Payable to Related Party [Member] | Subsequent Event [Member] | |||||||
Debt Instrument, Debt Default, Amount | $ 926,368 | ||||||
Convertible Debt to Related Party in Default [Member] | Subsequent Event [Member] | |||||||
Debt Instrument, Convertible, Number of Equity Instruments | 578,980 |
Note 9 - Convertible Notes - _4
Note 9 - Convertible Notes - Related Party - Convertible Notes Payable to Related Parties (Details) - Convertible Debt Payable to Related Party [Member] - USD ($) | Jun. 30, 2020 | Dec. 31, 2019 |
Long-term Debt | $ 2,558,681 | $ 2,558,681 |
Less: current portion | 2,558,681 | 2,538,681 |
Long-term portion loans payable - related party | 20,000 | |
Bill Chaaban, President of Cen Biotech [Member] | ||
Long-term Debt | 1,388,122 | 1,388,122 |
Director, Harold Aubrey de Lavenu [Member] | ||
Long-term Debt | 878,368 | 878,368 |
Director, Alex Tarrabain [Member] | ||
Long-term Debt | 48,000 | 48,000 |
Joseph Byrne [Member] | ||
Long-term Debt | 224,191 | 224,191 |
Brother of Director Ameen Ferris [Member] | ||
Long-term Debt | $ 20,000 | $ 20,000 |
Note 9 - Convertible Notes - _5
Note 9 - Convertible Notes - Related Party - Convertible Notes Payable to Related Parties (Details) (Parentheticals) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2020 | Dec. 31, 2019 | |
Director, Alex Tarrabain [Member] | ||
Interest Rate | 5.00% | 5.00% |
Conversion Rights | 30,000 | 30,000 |
Maturing Dates | Mar. 31, 2019 | Mar. 31, 2019 |
Brother of Director Ameen Ferris [Member] | ||
Interest Rate | 5.00% | 5.00% |
Conversion Rights | 12,500 | 12,500 |
Maturing Dates | Jun. 19, 2021 | Jun. 19, 2021 |
Convertible Debt Payable to Related Party [Member] | ||
Conversion Rights | 1,599,176 | |
Convertible Debt Payable to Related Party [Member] | Bill Chaaban, President of Cen Biotech [Member] | ||
Interest Rate | 12.00% | 12.00% |
Conversion Rights | 867,576 | 867,576 |
Maturing Dates | Aug. 17, 2020 | Aug. 17, 2020 |
Convertible Debt Payable to Related Party [Member] | Director, Harold Aubrey de Lavenu [Member] | ||
Interest Rate | 5.00% | 5.00% |
Conversion Rights | 548,980 | 548,980 |
Maturing Dates | Mar. 31, 2019 | Mar. 31, 2019 |
Convertible Debt Payable to Related Party [Member] | Joseph Byrne [Member] | ||
Interest Rate | 12.00% | 12.00% |
Conversion Rights | 140,120 | 140,120 |
Maturing Dates | Aug. 17, 2020 | Aug. 17, 2020 |
Note 10 - Income Taxes (Details
Note 10 - Income Taxes (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Operating Loss Carryforwards, Total | $ 28,400,000 | $ 28,400,000 | ||
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | $ 600,000 | $ (3,900,000) | $ 700,000 | $ (3,600,000) |
Note 10 - Income Taxes - Reconc
Note 10 - Income Taxes - Reconciliation of Effective Tax Rate (Details) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2020 | Dec. 31, 2019 | |
Income tax benefit at Canadian statutory rate | 26.50% | 26.50% |
Valuation allowance | (26.50%) | (26.50%) |
Effective income tax rate | 0.00% | 0.00% |
Note 10 - Income Taxes - Deferr
Note 10 - Income Taxes - Deferred Tax Assets (Details) - USD ($) | Jun. 30, 2020 | Dec. 31, 2019 |
Deferred tax asset - net operating losses | $ 7,500,000 | $ 6,800,000 |
Deferred tax asset valuation allowance | (7,500,000) | (6,800,000) |
Net deferred tax asset |
Note 11 - Shareholders' Defic_2
Note 11 - Shareholders' Deficit / Stock Activity (Details Textual) - $ / shares $ / shares in Thousands | Jun. 30, 2020 | Dec. 31, 2019 |
Common Stock, No Par Value (in dollars per share) | $ 0 | $ 0 |
Convertible Debt [Member] | ||
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 5,424,999 |
Note 12 - Related Party Trans_3
Note 12 - Related Party Transactions (Details Textual) | Oct. 01, 2017CAD ($) | Sep. 30, 2022CAD ($) | Jun. 30, 2020USD ($) | Jun. 30, 2019USD ($) | Jun. 30, 2020USD ($) | Jun. 30, 2019USD ($) | Dec. 31, 2017USD ($) | Jan. 31, 2018CAD ($) | Mar. 31, 2020a | Dec. 31, 2019USD ($) | Mar. 31, 2019USD ($) | Dec. 14, 2017 | Dec. 02, 2017 | Jul. 12, 2017 |
Area of Land (Acre) | a | 10.4 | |||||||||||||
Operating Lease, Right-of-Use Asset | $ 195,703 | $ 195,703 | $ 229,284 | |||||||||||
Operating Lease, Liability, Total | 197,184 | 197,184 | ||||||||||||
Lease Arrangement, 20 North Rear Road [Member] | ||||||||||||||
Operating Lease, Monthly Rent | $ 4,000 | |||||||||||||
Lessee, Operating Lease, Term of Contract (Year) | 5 years | |||||||||||||
Operating Lease, Right-of-Use Asset | 49,963 | 49,963 | $ 68,547 | |||||||||||
Operating Lease, Liability, Total | $ 47,028 | $ 47,028 | $ 65,467 | |||||||||||
Lessee, Operating Lease, Discount Rate | 8.00% | 8.00% | 8.00% | |||||||||||
Operating Lease, Expense | $ 8,690 | $ 9,106 | $ 17,409 | $ 15,092 | ||||||||||
Leases Office Space from R&D Labs Canada, Inc [Member] | ||||||||||||||
Operating Lease, Monthly Rent | $ 2,608 | $ 3,390 | ||||||||||||
Operating Lease, Right-of-Use Asset | 145,740 | 145,740 | $ 160,737 | |||||||||||
Operating Lease, Liability, Total | $ 150,156 | $ 150,156 | $ 163,157 | |||||||||||
Lessee, Operating Lease, Discount Rate | 8.00% | 8.00% | 8.00% | |||||||||||
Operating Lease, Expense | $ 6,928 | 7,060 | $ 13,253 | 12,039 | ||||||||||
Former CEO [Member] | ||||||||||||||
Ownership Percentage | 5.00% | 5.00% | ||||||||||||
Long-term Convertible Notes Payable to Multiple Private Investors [Member] | ||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | |||||||||||||
CEN Biotech Ukraine [Member] | XN Pharma [Member] | ||||||||||||||
Ownership Percentage | 49.00% | 49.00% | 49.00% | |||||||||||
CEN Biotech Ukraine [Member] | ||||||||||||||
Percentage of Related Party's Equity Interest Owned by Director | 25.50% | |||||||||||||
Business Acquisition, Percentage of Voting Interests Acquired | 51.00% | |||||||||||||
CEN Biotech Ukraine [Member] | ||||||||||||||
Due from Related Parties, Total | $ 1,065,328 | $ 1,065,328 | $ 1,065,328 | |||||||||||
Percentage of Related Party's Equity Interest Owned by Director | 51.00% | |||||||||||||
CEN Biotech Ukraine [Member] | Equipment Sold to Related Party in Exchange for Note Receivable [Member] | ||||||||||||||
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings | $ 255,141 | |||||||||||||
Notes Receivable, Related Parties | 44,859 | |||||||||||||
Joseph Byrne [Member] | ||||||||||||||
Related Party Transaction, Due from (to) Related Party, Current, Total | (8,347) | (8,347) | ||||||||||||
Board Members and Officers [Member] | Consulting Fees [Member] | ||||||||||||||
Related Party Transaction, Amounts of Transaction | 31,200 | $ 33,800 | 62,400 | $ 65,000 | ||||||||||
Due to Related Parties, Total | $ 267,800 | $ 267,800 | $ 263,900 | |||||||||||
R&D Labs Canada, Inc [Member] | Purchased Equipment in Exchange for Note Payable [Member] | ||||||||||||||
Notes Payable, Related Parties | $ 300,000 |
Note 12 - Related Party Trans_4
Note 12 - Related Party Transactions - Future Minimum Operating Lease Payments (Details) | Jun. 30, 2020USD ($) |
2020 | $ 58,188 |
2021 | 49,382 |
2022 | 28,130 |
2023 | 29,852 |
2024 | 29,852 |
Thereafter | 67,167 |
Total lease payments | 262,571 |
Less imputed interest | 65,387 |
Present value of lease liabilities | $ 197,184 |
Note 13 - Stock Based Compens_3
Note 13 - Stock Based Compensation (Details Textual) - USD ($) | Apr. 17, 2020 | Apr. 02, 2020 | Oct. 01, 2019 | May 16, 2019 | Dec. 31, 2018 | Jun. 19, 2018 | Jun. 07, 2018 | Nov. 30, 2017 | Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | Dec. 31, 2019 | Jun. 30, 2020 | Nov. 29, 2017 |
Stock Issued During Period, Shares, Issued for Services (in shares) | 225,000 | 50,000 | 12,120 | 125,000 | |||||||||||
Stock Issued During Period, Value, Issued for Services | $ 162,000 | $ 36,000 | $ 162,000 | ||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 782,250 | $ 782,250 | $ 782,250 | ||||||||||||
President [Member] | |||||||||||||||
Employment Agreement, Base Annual Salary | $ 31,200 | ||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 8,750,000 | ||||||||||||||
President [Member] | Vested Immediately [Member] | |||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 7,400,000 | ||||||||||||||
Chief Executive Officer [Member] | |||||||||||||||
Employment Agreement, Base Annual Salary | $ 31,200 | ||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 1,250,000 | ||||||||||||||
Accrued Salaries | $ 58,500 | ||||||||||||||
Number of Restricted Shares to settle Accrued Salaries (in shares) | 337,500 | ||||||||||||||
Chief Executive Officer [Member] | Vested Immediately [Member] | |||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 325,000 | ||||||||||||||
Senior Executive Vice President and Chief Financial Officer [Member] | |||||||||||||||
Employment Agreement, Base Annual Salary | $ 31,200 | ||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 4,500,000 | ||||||||||||||
Senior Executive Vice President and Chief Financial Officer [Member] | Vested Immediately [Member] | |||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 4,140,000 | ||||||||||||||
Vice President [Member] | |||||||||||||||
Employment Agreement, Base Annual Salary | $ 31,200 | ||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 750,000 | ||||||||||||||
Vice President [Member] | Vested Immediately [Member] | |||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 300,000 | ||||||||||||||
Chief Financial Officer [Member] | |||||||||||||||
Employment Agreement, Base Annual Salary | $ 31,200 | ||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 1,250,000 | ||||||||||||||
Chief Financial Officer [Member] | Vested Immediately [Member] | |||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 350,000 | ||||||||||||||
Restricted Stock [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 225,000 | 1,250,000 | 225,000 | 1,250,000 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 900,000 | 712,500 | 1,237,500 | 1,050,000 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grant DateFair Value | $ 12,896,241 | $ 12,734,241 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value | $ 162,000 | $ 1,262,500 | 162,000 | $ 1,262,500 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value | 459,000 | 588,000 | 697,500 | 797,250 | |||||||||||
Share-based Payment Arrangement, Expense | 196,650 | $ 546,150 | 393,300 | $ 713,550 | |||||||||||
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount | 782,250 | $ 782,250 | 782,250 | ||||||||||||
Restricted Stock [Member] | Consulting Expense [Member] | |||||||||||||||
Share-based Payment Arrangement, Expense | $ 162,000 | $ 162,000 | |||||||||||||
Restricted Stock [Member] | President [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 20,000 | ||||||||||||||
Restricted Stock [Member] | Director,Donald Strilchuck [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 20,000 | ||||||||||||||
Restricted Stock [Member] | Director Usamakh Saadikh [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 20,000 | ||||||||||||||
Restricted Stock [Member] | Chief Executive Officer [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 20,000 | ||||||||||||||
Restricted Stock [Member] | Senior Executive Vice President and Chief Financial Officer [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 20,000 | ||||||||||||||
Restricted Stock [Member] | Vice President [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 20,000 | ||||||||||||||
Restricted Stock [Member] | Director, Alex Tarrabain [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 20,000 | ||||||||||||||
Restricted Stock [Member] | Director, Harold Aubrey de Lavenu [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 20,000 | ||||||||||||||
Restricted Stock [Member] | Director, Ameen Ferris [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 20,000 | ||||||||||||||
Restricted Shares Issued for Security Consulting Services [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,870,000 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 1,330,000 | ||||||||||||||
Restricted Shares Issued for Security Consulting Services [Member] | Director,Donald Strilchuck [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,000,000 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 550,000 | ||||||||||||||
2017 Equity Compensation Plan [Member] | |||||||||||||||
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 20,000,000 |
Note 13 - Stock Based Compens_4
Note 13 - Stock Based Compensation - Restricted Stock Award Activity (Details) - Restricted Stock [Member] - $ / shares | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | |
Non-vested, number of share (in shares) | 2,025,000 | 2,612,500 | 2,612,500 | |||
Non-vested, weighted average grant date fair value (in dollars per share) | $ 0.76 | $ 0.62 | $ 0.62 | |||
Non-vested, weighted average remaining contractual term (Year) | 1 year 127 days | 1 year 354 days | 1 year 197 days | 2 years | ||
Granted, number of share (in shares) | 225,000 | 1,250,000 | 225,000 | 1,250,000 | ||
Granted, weighted average grant date fair value (in dollars per share) | $ 0.72 | $ 1.01 | ||||
Vested, number of share (in shares) | (900,000) | (712,500) | (1,237,500) | (1,050,000) | ||
Vested, weighted average grant date fair value (in dollars per share) | $ 0.68 | $ 0.83 | ||||
Forfeited, number of share (in shares) | ||||||
Forfeited, weighted average grant date fair value (in dollars per share) | ||||||
Non-vested, number of share (in shares) | 1,012,500 | 2,812,500 | 1,012,500 | 2,812,500 | 2,025,000 | 2,612,500 |
Non-vested, weighted average grant date fair value (in dollars per share) | $ 0.84 | $ 0.74 | $ 0.84 | $ 0.74 | $ 0.76 | $ 0.62 |
Note 14 - Net Loss Per Share -
Note 14 - Net Loss Per Share - Antidilutive Securities (Details) - shares | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Convertible Debt Securities [Member] | ||||
Antidilutive Securities (in shares) | 5,482,166 | 4,882,922 | 5,376,040 | 4,746,243 |
Note 16 - Fair Value Disclosu_3
Note 16 - Fair Value Disclosures - Fair Value of Financial Instruments (Details) - USD ($) | Jun. 30, 2020 | Dec. 31, 2019 |
Reported Value Measurement [Member] | ||
Cash and cash equivalents | $ 8,440 | $ 3,757 |
Other receivables | 349,003 | 424,110 |
Note receivable - related party | 44,859 | 44,859 |
Advances to CEN Biotech Ukraine, LLC - related party | 1,065,328 | 1,065,328 |
Loans payable | 10,107,513 | 10,121,411 |
Loans payable – related parties | 1,360,845 | 1,362,600 |
Patent acquisition liability | 720,000 | 720,000 |
Convertible notes payable | 6,434,445 | 6,224,325 |
Convertible notes payable – related parties | 2,558,681 | 2,558,681 |
Estimate of Fair Value Measurement [Member] | ||
Cash and cash equivalents | 8,440 | 3,757 |
Other receivables | 349,003 | 424,110 |
Note receivable - related party | 44,859 | 44,859 |
Advances to CEN Biotech Ukraine, LLC - related party | 1,065,328 | 1,065,328 |
Loans payable | 10,107,513 | 10,121,411 |
Loans payable – related parties | ||
Patent acquisition liability | 720,000 | 720,000 |
Convertible notes payable | 7,283,393 | 6,918,486 |
Convertible notes payable – related parties | ||
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Cash and cash equivalents | ||
Other receivables | ||
Note receivable - related party | ||
Advances to CEN Biotech Ukraine, LLC - related party | ||
Loans payable | ||
Loans payable – related parties | ||
Patent acquisition liability | ||
Convertible notes payable | ||
Convertible notes payable – related parties | ||
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] | ||
Cash and cash equivalents | 8,440 | 3,757 |
Other receivables | ||
Note receivable - related party | ||
Advances to CEN Biotech Ukraine, LLC - related party | ||
Loans payable | ||
Loans payable – related parties | ||
Patent acquisition liability | ||
Convertible notes payable | ||
Convertible notes payable – related parties | ||
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] | ||
Cash and cash equivalents | ||
Other receivables | 349,003 | 424,110 |
Note receivable - related party | 44,859 | 44,859 |
Advances to CEN Biotech Ukraine, LLC - related party | 1,065,328 | 1,065,328 |
Loans payable | 10,107,513 | 10,121,411 |
Loans payable – related parties | ||
Patent acquisition liability | 720,000 | 720,000 |
Convertible notes payable | 7,283,393 | 6,918,486 |
Convertible notes payable – related parties |
Note 17 - Subsequent Events (De
Note 17 - Subsequent Events (Details Textual) - Subsequent Event [Member] | 1 Months Ended |
Jul. 30, 2020USD ($) | |
Convertible Notes Payable, Total | $ 24,000 |
Debt Instrument, Convertible, Number of Equity Instruments | 15,000 |